TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04053829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOLOBalance
Description: The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OTAGO Home Exercise Programme
Description: The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
Study: NCT03888820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Study: NCT03379415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Footwear
Description: Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait analysis will be done during several different tasks wear the footwear
Study: NCT01487564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone 16 mg
Description: type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
Study: NCT02560103

Intervention type: OTHER
Intervention: Transmeridian travel across multiple time zones
Study: NCT04371718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122
Description: JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
Study: NCT00964873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090 (ganetespib)
Description: Chemotherapy agent
Study: NCT02192476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional neuro rehabilitation programme
Description: All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional neuro rehabilitation programme
Description: All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: California tri-pull taping (CTPT)
Description: Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape.
Study: NCT01892189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.
Study: NCT04371718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122
Description: JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule has same component but active drug
Study: NCT03136263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
Study: NCT02893228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline
Description: At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
Study: NCT01644773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day
Study: NCT02771418

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
Study: NCT02780063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lenstar Biometer
Description: uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
Study: NCT03594734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance™
Description: The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication.
Study: NCT00569270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Study: NCT02771418

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Elective carotid endarterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective carotid endarterectomy
Study: NCT00569270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Study: NCT04189575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Intervention
Description: Delivery of text messages will use the Rip Road Mobile platform.
Study: NCT02857582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured human intestinal microbiota
Description: Secondary treatment for C diff in replacement for regular vancomycin.
Study: NCT01892189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.
Study: NCT02857582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured human intestinal microbiota
Description: Secondary treatment for C diff in replacement for regular vancomycin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Active comparator to treatment with ACHIM
Study: NCT03561558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen D
Description: Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen® for Children
Description: Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
Study: NCT03098186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention SMS
Description: The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control SMS
Description: Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Study: NCT04542915

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study: NCT04461340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
Study: NCT01601938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium replacement
Description: Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
Study: NCT02312479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nyxoah SAT system
Description: The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
Study: NCT01936311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management goal elicitation
Description: The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
Study: NCT02857582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Primary treatment for C diff in all treatment arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Primary treatment for C diff in all treatment arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Primary treatment for C diff in all treatment arms
Study: NCT03287687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) gas insufflation
Description: CO2 gas use for insufflation during endoscopy instead of air insufflation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air insufflation is the standard of practice (used in the control arm)
Study: NCT04293731

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter-Smectite
Description: Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02728622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: endocrine treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Paclitaxel or pegylated liposomal doxorubicin
Study: NCT02662634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003-LNG
Description: autologous dendritic cell immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003-LNG
Description: autologous dendritic cell immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003-LNG
Description: autologous dendritic cell immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003-LNG
Description: autologous dendritic cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
Study: NCT01264913

Intervention type: BEHAVIORAL
Intervention: sleep extension & circadian alignment
Description: Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system

Intervention type: BEHAVIORAL
Intervention: sleep extension & circadian alignment
Description: Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
Study: NCT02662634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Mechanism of action involves interference with the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Mechanism of action involves interference with the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Mechanism of action involves interference with the normal breakdown of microtubules during cell division.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Mechanism of action involves interference with the normal breakdown of microtubules during cell division.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Causes DNA strand breaks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Causes DNA strand breaks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Causes DNA strand breaks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Causes DNA strand breaks.
Study: NCT01736462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
Study: NCT02091908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Investigational H5N1 vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Investigational H5N1 vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Seasonal Influenza Vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Seasonal Influenza Vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart